{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:09:48Z","timestamp":1791328188307,"version":"4.3.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0122000","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T17:15:16Z","timestamp":1427476516000},"page":"e0122000","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica"],"prefix":"10.1371","volume":"10","author":[{"given":"Fumitaka","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuteru","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,3,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"DM Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"DM Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"VA Lennon","year":"2004","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"SR Hinson","year":"2007","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","article-title":"Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment","volume":"181","author":"T Vincent","year":"2008","journal-title":"J Immunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"MC Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"M Bradl","year":"2009","journal-title":"Ann Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-010-0704-z","article-title":"Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination","volume":"120","author":"R Sharma","year":"2010","journal-title":"Acta Neuropathol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"S Saadoun","year":"2010","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/2051-5960-1-85","article-title":"T cell-activation in neuromyelitis optica lesions plays a role in their formation","volume":"1","author":"M Pohl","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2051-5960-1-5","article-title":"Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats","volume":"1","author":"M Kitic","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneurol.2011.148","article-title":"Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica","volume":"68","author":"A Uzawa","year":"2011","journal-title":"Arch Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"A Uzawa","year":"2014","journal-title":"Brain Pathol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e61835","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"T Matsushita","year":"2013","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","article-title":"Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients","volume":"120","author":"S I\u00e7\u00f6z","year":"2010","journal-title":"Int J Neurosci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","article-title":"Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks","volume":"421","author":"A Uzawa","year":"2013","journal-title":"Clin Chim Acta"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"A Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"T Misu","year":"2007","journal-title":"Brain"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica","volume":"24","author":"CF Lucchinetti","year":"2014","journal-title":"Brain Pathol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jnnp-2011-300434","article-title":"Sera from neuromyelitis optica patients disrupt the blood-brain barrier","volume":"83","author":"F Shimizu","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/jnnp-2013-305907","article-title":"Autocrine MMP-2\/9 secretion increases the BBB permeability in neuromyelitis optica","volume":"85","author":"A Tasaki","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"T Takahashi","year":"2007","journal-title":"Brain"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"CH Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/jcp.22232","article-title":"Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function","volume":"225","author":"Y Sano","year":"2010","journal-title":"J Cell Physiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/brain\/awh453","article-title":"Intrathecal activation of the IL-17\/IL-8 axis in opticospinal multiple sclerosis","volume":"128","author":"T Ishizu","year":"2005","journal-title":"Brain"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.0b013e3181c1deb9","article-title":"Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis","volume":"73","author":"K Yanagawa","year":"2009","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jneuroim.2003.12.010","article-title":"CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis","volume":"149","author":"K Narikawa","year":"2004","journal-title":"J Neuroimmunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-0404.2006.00749.x","article-title":"Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies","volume":"115","author":"A Szczuci\u0144ski","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.4049\/jimmunol.166.12.7617","article-title":"CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis","volume":"166","author":"BT Fife","year":"2001","journal-title":"J Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1172\/JCI25141","article-title":"IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis","volume":"115","author":"AI Kaplin","year":"2005","journal-title":"J Clin Invest"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jns.2013.05.035","article-title":"NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement","volume":"331","author":"H Haruki","year":"2013","journal-title":"J Neurol Sci"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"BC Kieseier","year":"2013","journal-title":"JAMA Neurol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"I Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"ref34","first-page":"157","article-title":"Neuron-Glia Interaction in Neuroinflammation","author":"F Shimizu","year":"2013"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbadis.2010.06.017","article-title":"Disruption of central nervous system barriers in multiple sclerosis","volume":"1812","author":"JI Alvarez","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1089\/neu.2012.2651","article-title":"The therapeutic role of interleukin-10 after spinal cord injury","volume":"30","author":"CD Thompson","year":"2013","journal-title":"J Neurotrauma"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e92872","DOI":"10.1371\/journal.pone.0092872","article-title":"Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier","volume":"9","author":"F Shimizu","year":"2014","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0122000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T18:49:31Z","timestamp":1540234171000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0122000"}},"subtitle":[],"editor":[{"given":"Monika","family":"Bradl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,26]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0122000","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,26]]}}}